Physician profile
Sam Sadeghi
NPI 1053380949
$15,697.37
in general payments reported to CMS, 2019-2025
55 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,401 · 2020: $1,871 · 2021: $2,484 · 2022: $2,153 · 2023: $2,150 · 2024: $2,510 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,787.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,946.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,621.52 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,575.14 | 2020-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,528.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $1,106.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $842.45 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $637.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $466.90 | 2019-2025 | Veozah |
| Amgen INC. | $409.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $373.18 | 2021-2025 | |
| Abbott Laboratories | $355.97 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $337.31 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $280.58 | 2021-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $272.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $250.20 | 2019-2025 | Eliquis, Camzyos |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Sadeghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.